Pivotal enters into sales, distribution agreement for BeneFishial family of products

Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that it has entered into a Memorandum of Understanding with Korea Animal Medical Science Institute (KAMSI) and its newly created affiliate for the exclusive sales and distribution of the BeneFishial^™ family of products. The BeneFishial^™ family of products consists of the following six products: (i) BeneFishial^™ for overall health and well being, (ii) BeneFishial^™ for cardiovascular health, (iii) BeneFishial^™ for prenatal health, (iv) BeneFishial^™ for toddler's health, (v) BeneFishial^™ for child's health and (vi) BeneFishial^™ for pet's health (veterinary application).

The distribution agreement focuses on Pivotal's BeneFishial^™ line of products for the nutraceutical and veterinary markets in Korea and the veterinary market in Japan. The agreement also provides for an upfront payment and guaranteed minimum annual sales targets to be achieved.

"Pivotal is an attractive partner offering a large spectrum of patented formulations each delivering convincing health benefits to multiple user groups in Korea and Japan," said Mr. Cheolseung Peck, CEO of KAMSI's affiliate.

"We are delighted to partner with Korea's leading pre-clinical and regulatory contract research organization that will lead the way for Pivotal into this highly professional and competitive market place. Their unique experience in registering complex products including safety and reimbursement together with their proven international and U.S. experienced executive team provides a unique basis for a sustainably successful launch of our products in these important Asian markets that are Korea and Japan," said Mr. Eugene Bortoluzzi, Pivotal's CEO and CFO.